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adaptor-related protein complex 2 sigma subunit (AP2r)
mutations, located at the interface with the AP2 alpha
subunit, that impair calcium-sensing receptor signalling
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Abstract
Mutations of the sigma subunit of the heterotetrameric adaptor-related protein complex 2 (AP2r) impair signalling of the
calcium-sensing receptor (CaSR), and cause familial hypocalciuric hypercalcaemia type 3 (FHH3). To date, FHH3-associated
AP2r mutations have only been identified at one residue, Arg15. We hypothesized that additional rare AP2r variants may also
be associated with altered CaSR function and hypercalcaemia, and sought for these by analysing>111 995 exomes (>60 706
from ExAc and dbSNP, and 51 289 from the Geisinger Health System-Regeneron DiscovEHR dataset, which also contains clinical
data). This identified 11 individuals to have 9 non-synonymous AP2r variants (Arg3His, Arg15His (x3), Ala44Thr, Phe52Tyr,
Arg61His, Thr112Met, Met117Ile, Glu122Gly and Glu142Lys) with 3 of the 4 individuals who had Arg15His and Met117Ile AP2r
variants having mild hypercalcaemia, thereby indicating a prevalence of FHH3-associated AP2r mutations of7.8 per 100 000
individuals. Structural modelling of the novel eight AP2r variants (Arg3His, Ala44Thr, Phe52Tyr, Arg61His, Thr112Met,
Met117Ile, Glu122Gly and Glu142Lys) predicted that the Arg3His, Thr112Met, Glu122Gly and Glu142Lys AP2r variants would dis-
rupt polar contacts within the AP2r subunit or affect the interface between the AP2r and AP2a subunits. Functional analyses of
all eight AP2r variants in CaSR-expressing cells demonstrated that the Thr112Met, Met117Ile and Glu142Lys variants, located in
the AP2r a4-a5 helical region that forms an interface with AP2a, impaired CaSR-mediated intracellular calcium (Ca2þi ) signalling,
consistent with a loss of function, and this was rectified by treatment with the CaSR positive allosteric modulator cinacalcet.
Thus, our studies demonstrate another potential class of FHH3-causing AP2r mutations located at the AP2r-AP2a interface.
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Introduction
Familial hypocalciuric hypercalcaemia (FHH) is an autosomal
dominant condition characterized by lifelong mild-to-moderate
elevations of serum calcium concentrations in association with
normal or mildly raised serum parathyroid hormone (PTH)
concentrations and low urinary calcium excretion (1,2). FHH is
genetically heterogeneous and at present comprises three
reported subtypes (FHH1–3). FHH1 (OMIM #145980) is due to het-
erozygous loss-of-function mutations affecting the G-protein-
coupled calcium-sensing receptor (CaSR), encoded by the CASR
gene, and FHH2 (OMIM #145981) is due to heterozygous loss-of-
function mutations of the G-protein alpha-11 subunit (Ga11),
encoded by the GNA11 gene (3,4). The CaSR and Ga11 play a
critical role in systemic calcium homeostasis by detecting alter-
ations in extracellular calcium (Ca2þe) concentrations and initi-
ating multiple intracellular signalling cascades that include
phospholipase-C-mediated accumulation of inositol 1,4,5-tri-
sphosphate (IP3), and increases in intracellular calcium (Ca
2þ
i)
concentrations (5,6), which in turn leads to decreases in PTH se-
cretion and increases in urinary calcium excretion (7).
Familial hypocalciuric hypercalcaemia type 3 (FHH3) (OMIM
#600740) represents a clinically more severe form of FHH, which
may be associated with symptomatic hypercalcaemia, osteopo-
rosis, osteomalacia and cognitive dysfunction (8,9). FHH3 is
caused by mutations of the adaptor-related protein complex 2
(AP2) sigma subunit (AP2r), encoded by the AP2S1 gene which
consists of five exons (Fig. 1). AP2, which is a ubiquitously ex-
pressed heterotetrameric protein comprising a, b, m and r subu-
nits (10) (Supplementary Material, Fig. S1), plays a fundamental
role in the clathrin-mediated endocytosis of G-protein-coupled
receptors (GPCRs) such as the CaSR. The AP2 complex operates
as two heterodimers, one comprised of the AP2a and AP2r sub-
units, and the other the AP2b and AP2m subunits (11–13)
(Supplementary Material, Fig. S1). In the inactive state, the AP2a
and AP2b subunits form a diamond-shaped outer complex, and
the AP2m and AP2r subunits, are buried within the core of the
AP2 complex (10–12,14–16). Upon activation, AP2a and AP2b
bend away from each other, with the AP2r subunit accompany-
ing AP2a and the AP2m subunit being displaced toward the
plasma membrane (11,12,14). In this open conformation, the
AP2m and AP2r subunits bind to endocytic motifs on transmem-
brane cargo proteins, and thereby facilitate the association of
clathrin with the AP2 complex (12,14,17).
All three FHH3-associated mutations reported to date in-
volve the AP2r Arg15 residue (8,18–22), which is located within
the b2-strand (Fig. 2), and each of the three different missense
mutations (Arg15Cys, Arg15His or Arg15Leu) (Fig. 1), are postu-
lated to disrupt polar contacts between the AP2r Arg15 residue
and the dileucine motif within the intracellular domain of the
CaSR, which likely targets it for endocytosis (8,10,18). Indeed,
these three FHH3-associated AP2r Arg15 mutations have been
shown to alter CaSR cell-surface expression and to have a
dominant-negative effect on CaSR-mediated signalling (8,18). In
contrast, other potential mutations of the AP2r Arg15 residue
(Arg15Gly, Arg15Pro or Arg15Ser) have not been observed in hu-
mans, and in vitro studies have shown these mutations to im-
pair cell growth (8). These findings indicate that potential
mutations affecting the AP2S1 gene, which is highly conserved
in zebrafish, fruitfly and yeast homolog proteins with-
>99%,>96% and>95% amino acid identity, respectively, may
not be commonly observed as they affect cellular viability (13).
Moreover, the large exome and genome datasets contain AP2S1
variants at very low frequencies. For example, examination of
the>13 000 alleles from the exome variant server did not reveal
the presence of any AP2r variants, whilst the 1000Genomes and
Exome Aggregation Consortium (ExAc) databases (23,24) con-
tained only six coding variants, and the dbSNP database had
only one AP2r missense variant. The pathophysiological signifi-
cance of these rare coding AP2r variants is unknown, especially
as these large sequencing projects do not contain phenotype in-
formation on individuals. Thus, these rare coding AP2r variants
may be benign polymorphisms, and we have previously shown
that some AP2r variants do not alter CaSR signalling or result in
an abnormal phenotype. For example, our in vitro examination
of N-ethyl-N-nitrosourea (ENU) induced AP2r variants in mice
demonstrated that two missense AP2r variants, Tyr20Asn and
Ile123Asn, had no effect on CaSR signalling, and that mice het-
erozygous for a donor splice-site variant, which results in an
in-frame deletion of 17 amino acids, had normal serum and uri-
nary calcium, despite a>50% reduction in AP2r protein expres-
sion (25). This emphasises the need for in vitro and in vivo
functional assessments of AP2r variants, in determining their
potential role in the pathophysiology of calcium homeostasis.
The DiscovEHR exome sequencing dataset, which has arisen
from a collaboration between the Regeneron Genetics Center
and Geisinger Health System (26), offers a new opportunity for
studying the role of rare coding variants in human pathophysi-
ology, as the dataset contains matched genotype and pheno-
type information from 51 289 individuals (26). We therefore
investigated the DiscovEHR dataset, as well as the ExAc and
dbSNP datasets, to identify rare coding AP2r variants, and
characterized their functional and clinical consequences. These
studies demonstrated that AP2r variants located at the inter-
face between the AP2r and AP2a subunits were associated with
impaired CaSR signalling and hypercalcaemia.
Results
Identification of two AP2r variants associated with
hypercalcaemia in the DiscovEHR exome sequencing
dataset
An analysis of the DiscovEHR exome sequencing dataset,
which at the time of investigation contained the exomes from
51 289 adult patients (26), revealed five females to have hetero-
zygous coding AP2S1 variants (Supplementary Material, Table
S1, Fig. S1). Three of these patients harboured the reported
FHH3-causing Arg15His mutation located in exon 2 of AP2S1
(Fig. 1) (18), and two of these three patients were found to have
mild hypercalcaemia (Table 1). The other two patients had
novel variants which comprised: a heterozygous G-to-A transi-
tion at nucleotide c.155, located in exon 3, leading to substitu-
tion of the wild-type (WT) phenylalanine (Phe) with the mutant
tyrosine (Tyr) at residue 52 of the AP2r protein; and a heterozy-
gous G-to-T transversion at nucleotide c.350, located in exon 5,
resulting in a missense substitution of the WT methionine (Met)
to a mutant isoleucine (Ile) at residue 117 of the AP2r protein
(Fig. 1, Supplementary Material, Table S1). The novel Phe52Tyr
and Met117Ile variants, which were observed only once in the
DiscovEHR dataset and were absent in the ExAc dataset, af-
fected evolutionarily conserved AP2r residues (Fig. 1), and as-
sessments using the SIFT and Polyphen-2 prediction software
(27,28) revealed the following. SIFT predicted that both of these
variants would be disease-causing or damaging, whilst
Polyphen-2 predicted that Phe52Tyr would be tolerated, but that
the Met117Ile was likely to be damaging (Supplementary
Material, Table S1). The Polyphen-2 predictions were found to
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be in agreement with the results of the serum calcium concen-
trations obtained from the Geisinger Health System electronic
health records (Table 1), which revealed that the patient with
the Phe52Tyr variant was normocalcaemic, but that the patient
harbouring the Met117Ile AP2r variant had mild hypercalcae-
mia (Table 1). Thus, these studies reveal that 4 out of 51 289 in-
dividuals in the DiscovEHR cohort harboured AP2r variants that
were associated with hypercalcaemia and/or FHH3, thereby in-
dicating an overall prevalence of 7.8 per 100 000 for disease-
causing AP2r variants in this cohort.
Identification of six non-synonymous AP2r variants
within the ExAc and dbSNP databases
The identification of a non-Arg15 AP2r variant that was associ-
ated with a mild elevation of serum calcium concentration
(Fig. 1 and Table 1) suggested that additional rare AP2r variants
that may disrupt calcium homeostasis may also be present in
exome sequence databases. We therefore searched for AP2S1
variants in>60 706 unrelated individuals in the ExAc (24),
1000Genomes (23) and dbSNP datasets (Supplementary
Material, Tables S2 and S3). This identified 27 AP2r variants,
which comprised 6 non-synonymous germline variants and 21
synonymous variants (Fig. 1, Supplementary Material, Tables S2
and S3). Variants involving the AP2r Arg15 residue were not
identified and there were also no nonsense mutations of AP2r.
This number of non-synonymous AP2r variants was signifi-
cantly lower than the expected numbers of missense (n¼ 63.7)
and nonsense (n¼ 7.8) variants for a protein of 142 amino acids,
estimated using the ExAc database (24) (observed AP2r variants
vs. expected gene variants: missense¼ 0.009% vs. 0.1%; and
nonsense¼ 0% vs. 0.01%, v2 ¼ P< 0.0001). Two of the non-
synonymous AP2r variants were found in exon 2, and consisted
of Arg3His (G>A at c.8) and Ala44Thr (C>T at c.130), one non-
synonymous AP2r variant Arg61His (C>T at c.182) was found
in exon 3, and the remaining three non-synonymous variants
were identified in exon 5, and consisted of Thr112Met (C>T at
c.335), Glu122Gly (A>G at c.365) and Glu142Lys (G>A at c.424).
All of these six non-synonymous variants, which were observed
only once in the ExAc or dbSNP datasets and were not present
in the DiscovEHR dataset, affected evolutionarily conserved res-
idues (Fig. 1B and C), thereby, indicating they may represent
pathogenic mutations rather than benign polymorphisms.
Structural characterization of eight novel AP2r variants
The predicted effects of the eight novel non-synonymous AP2r
variants, which comprised two from the DiscovEHR dataset
(Phe52Tyr and Met117Ile), five from the ExAc dataset (Arg3His,
Arg61His, Thr112Met, Glu122Gly and Glu142Lys) and one from
Figure 1. Schematic representation of AP2S1 gene showing locations of the identified variants. (A) Representation of the genomic organization of the human AP2S1
gene showing the location of the identified variants. The AP2S1 gene consists of 5 exons (shaded) with the start (ATG) and stop (TGA) codons located in exons 1 and 5,
respectively. Untranslated regions are represented by open boxes. The Arg (R)15 residue (indicated in grey with a solid line), at which the previously reported FHH3-as-
sociated mutations of Cys (C), His (H) and Leu (L) have been identified (18), is located in exon 2. Two novel AP2r variants, Phe52Tyr (F52Y) and Met117Ile (M117I), identi-
fied in the DiscovEHR cohort are located within exons 3 and 5, respectively (indicated by a broken line above the exons). The six AP2r variants [Arg3His (A3H), Ala44Thr
(A44T), Arg61His (R61H), Thr112Met (T112M), Glu122Gly (E122G) and Glu142Lys (E142K)] identified in the ExAc and dbSNP databases are located in exons 2, 3 and 5, and
are shown (by solid lines) below the exons. (B–C) Multiple protein sequence alignment of residues comprising (B) the b1–b5 strands and the a1 helix (residues 1–69) and
(C) the a4 and a5 helices (residues 107–142) of AP2r-subunit orthologs encoded by AP2S1 exons 2, 3 and 5. Conserved residues are shaded grey. The WT and variant res-
idues are shown in red. The FHH3-associated R15H mutation is shown in blue. The R3, A44, F52, R61, T112, M117, E122 and E142 residues are evolutionarily conserved,
thereby indicating that they likely have important structure–function roles in AP2r.
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dbSNP (Ala44Thr), on the structure of the AP2r protein and their
interactions with other subunits within the AP2 complex were
characterized (Fig. 2). The eight AP2r variants were found not to
alter the secondary structure of the AP2r a-helical or b-strand
structures. Three-dimensional modelling of the AP2r variants
was undertaken using the reported crystal structure of the AP2
heterotetramer (12). The AP2r subunit is comprised of five a-he-
lices and a cluster of five b-strands (12), and the analysis of
three-dimensional modelling, revealed that four of the variants
were situated in the b-strand cluster, which is involved in the
binding of the AP2r subunit to the cargo protein dileucine motif
(10) (Fig. 2), and the other four variants were located in the a4
and a5 helices, which lie close to the AP2a subunit, that forms a
heterodimer with AP2r (11,12) (Fig. 3 and Supplementary
Material, Fig. S1). Further analysis of the four variants (Arg3His,
Ala44Thr, Phe52Tyr and Arg61His) within the b-strand cluster,
revealed that the Arg3His variant, which is located distal to
Arg15 in the b1-strand (Fig. 2B), would likely disrupt a polar con-
tact between the WT Arg3 residue and the Asp72 residue on the
b5-a2 loop (Fig. 2C), and this would potentially impair stability
of the AP2r subunit. However, the Ala44Thr and Phe52Tyr vari-
ants, which are located in the a1-b3 loop and the b3-strand of
the AP2r subunit, respectively, were not predicted to disrupt in-
tra- or inter-subunit interactions (Fig. 2D and E), but the
Arg61His variant, which is located in the b4-strand and close to
the site of the dileucine binding motif of membrane cargo pro-
teins, was predicted to potentially disrupt the binding of AP2r
to membrane cargo proteins (Fig. 2F and G).
Similar analysis of the four variants (Thr112Met, Met117Ile,
Glu122Gly and Glu142Lys) located in the a4-a5 region at the
C-terminus of the AP2r protein (Fig. 2), revealed that the
Thr112Met, Glu122Gly and Glu142Lys variants, would likely dis-
rupt AP2r-AP2a inter-subunit interactions, and thereby impair
the structural integrity of this heterodimer and/or activation of
Figure 2. Structural characterization of the AP2r variants encoded by AP2S1 exons 2 and 3. (A) Close-up view of the AP2 r-subunit with the residues having variants
within the ExAc (Arg3His, Arg61His, Thr112Met, Glu122Gly and Glu142Lys), dbSNP (Ala44Thr) and DiscovEHR (Phe52Tyr and Met117Ile) cohorts shown in red. The FHH3
mutations affect the Arg15 residue (shown in blue). (B) The AP2r Arg3 residue is located within the b1 strand that lies adjacent to the b2 strand in which the FHH3-asso-
ciated Arg15 residue is located. Arg3 forms polar contacts with residues Tyr20, Cys70, Asp72 on the adjacent b2-a1 loop, b4-strand and b4-b5 loop, respectively. (C)
Mutation of the Arg3 residue to His3 leads to loss of the polar contact with Asp72, which may disrupt the stability of the r-subunit. (D) The Ala44 residue is located in
the a1-b3 loop, and the Phe52 residue is located distal to this, in the b3 strand. Ala44 is not predicted to form polar contacts with any neighbouring residues, while
Phe52 is predicted to form polar contacts with the adjacent Phe55 located in the b4 strand. (E) Mutation of the Ala44 and Phe52 residues to Thr44 and Tyr52, respec-
tively, are not predicted to disrupt or form new contacts with other AP2r residues. (F) The Arg61 residue is located in the b4 strand that lies within a cluster of b-strands
that converge close to the Arg15 AP2r residue and the dileucine motif binding site (black) of cargo proteins, such as the CaSR and other GPCRs. (G) Mutation of Arg61 to
His61 may affect binding to the cargo protein dileucine recognition motif.
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Table 1. Genotypes and phenotypes of five patients with AP2S1 variants from the DiscovEHR cohort
Nucleotide
change
Predicted
change
Sexa Age
(years)
Total serum calcium
adjusted for albumin
(mg/dL)b,c
Co-existing clinical conditions
c.44G>A Arg15His F 72 10.06 Polycystic kidney disease, hypothyroidism, hypertension, dia-
betes mellitus type 2, vitamin D deficiency, osteoporosis
c.44G>A Arg15His F 68 10.08 Multiple sclerosis, vitamin D deficiency, osteoporosis, obesity
c.44G>A Arg15His F 73 9.80 Pituitary tumour, asthma
c.155G>A Phe52Tyr F 53 9.56 Obesity, vitamin D deficiency, hypothyroidism
c.350G>T Met117Ile F 34 10.10d —e
aF, female.
bSerum calcium normal range¼8.30–10.00 mg/dL, which is defined as the mean6 2 standard deviations (SD). Hypercalcaemia is defined as a serum calcium concentra-
tion greater than 2 SDs above the normal mean, and hypercalcaemia is generally considered to be mild, moderate or severe for serum calcium concentrations that
are>10.00 mg/dL but12.00 mg/dL, between 12.01 and 14.00 mg/dL, and14.01 mg/dL, respectively (40). The serum calcium concentrations are adjusted or ‘corrected’
to a reference (usually the mean for the normal population) albumin concentration, because 50% of total serum calcium is bound to albumin, and thus variations in
serum albumin concentration can affect total serum calcium concentrations (40). The formula used to derive the total serum calcium concentration adjusted for albu-
min is: adjusted total serum calcium concentration¼measured total serum calciumþ [0.8  (4.0 – measured total serum albumin concentrations)] (40).
cThe initial serum calcium value obtained from ambulatory patients in the outpatient department is shown.
dSerum albumin is not available for this patient, and the uncorrected total serum calcium concentration is shown.
e—, clinical details not available.
Figure 3. Structural characterization of the AP2r variants within the AP2r a4-a5 helices encoded by AP2S1 exon 5. (A) Structural model of the a4-helix of the AP2r subu-
nit (shown in light brown) with the adjacent a5-helix of the AP2a subunit (shown in blue). The Thr112 residue forms a polar contact with the Tyr108, Lys109 and Glu116
residues on the a4-helix of AP2r, and the Gln92 residue on the a5-helix of the AP2a subunit. (B) Mutation of the Thr112 residue to Met112 leads to loss of the polar con-
tact with Gln92, and therefore may impair AP2r–AP2a subunit interactions. (C) Structural model of the a4–a5 helices of the AP2r subunit (shown in light brown) with
the adjacent a12-helix of the AP2a subunit (shown in blue). The Glu122 residue is located within the a4–a5 loop, and forms polar contacts with Leu119 of the AP2r subu-
nit, and Ser209 in the a12-helix of the AP2a subunit. (D) Mutation of residue Glu122 to Gly122 results in loss of the contact with Ser209, and thus the Gly122 variant may
impair AP2r–AP2a subunit interactions. (E) Structural model of the a4 and a5 helices of AP2r (shown in light brown) and the AP2a subunit (shown in blue). The Glu142
residue is located at the end of the a4-helix of the AP2r subunit and forms polar contacts with Gly9, Lys56 and Tyr88 of the AP2a subunit. (F) Mutation of the Glu142 res-
idue to Lys142 disrupts the polar contact with Lys56, and thus the Lys142 variant may impair AP2r–AP2a subunit interactions. (G) Structural model of the a4 helix of
AP2r (shown in light brown) with the Met117 residue indicated in red. The Met117 residue forms polar contacts with Val113, Val114 and Arg124. (H) Mutation of the
Met117 residue to Ile117 is not predicted to alter residue hydrophobicity and disrupt these polar contacts.
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the AP2 complex (Fig. 3A–F). However, the side chain of Met117
and the variant Ile117 face away from the AP2r–AP2a interface,
and thus the Met117Ile variant was not predicted to alter inter-
actions with the AP2a subunit, or to disrupt contacts within the
AP2r a4-helix (Fig. 3G and H). The consequences of all these pre-
dicted structural alterations resulting from the AP2r variants,
on CaSR-mediated signalling were further assessed (Fig. 4 and
Supplementary Material, Figs S2 and S3).
Effects of the eight novel AP2r variants on CaSR-
mediated signalling and treatment with cinacalcet
To determine the effects of the AP2r variants on CaSR-mediated
signalling, HEK293 cells stably expressing the CaSR (HEK-CaSR)
were transiently transfected with pBI-CMV4-AP2S1 constructs ex-
pressing either the WT or mutant AP2r proteins, as described (8).
This bidirectional pBI-CMV4 vector allowed for co-expression of
AP2r and red fluorescent protein (RFP) at equivalent levels, as re-
ported previously (8). The expression of AP2r and RFP was con-
firmed by fluorescence microscopy and/or western blot analyses
(Supplementary Material, Fig. S2A and B). The expression of AP2r
was shown to be similar in cells transiently transfected with WT
or variant proteins and higher than the endogenous expression of
AP2r (Supplementary Material, Fig. S2B). The Ca2þe-induced Ca
2þ
i
responses of HEK-CaSR cells transiently expressing the AP2r vari-
ants was assessed using a flow cytometry-based assay, as de-
scribed (18). The reported FHH3-causing Arg15His AP2r variant
(18) was used as a loss-of-function control in the flow cytometry
assays. The Ca2þi responses in WT and variant AP2r-expressing
cells increased in a dose-dependent manner following exposure to
increasing concentrations of Ca2þe. However, responses in cells
expressing the Thr112Met, Met117Ile or Glu142Lys AP2r variants,
which are all located in the a4-a5 helical region of the AP2r subu-
nit (Fig. 3), were significantly reduced when compared to WT ex-
pressing cells (Fig. 4A–C), consistent with these AP2r variants
leading to loss of CaSR function (18). Thus, the Thr112Met,
Met117Ile and Glu142Lys variants and Arg15His mutant express-
ing cells showed a rightward shift in the concentration–response
curves (Fig. 4A–C), with significantly increased half-maximal (EC50)
values (n¼ 4–8) of 3.39 mM [95% confidence interval (CI) 3.26–3.53
mM] for Thr112Met expressing cells (P< 0.001), 3.41 mM (95% CI
3.29–3.54 mM) for Met117Ile expressing cells (P< 0.001), 3.63 mM
(95% CI 3.49–3.78 mM) for Glu142Lys expressing cells (P< 0.0001)
and 3.66 mM (95% CI 3.52–3.81 mM) for Arg15His expressing cells
(P< 0.0001), compared to 2.87 mM (95% CI 2.74–3.00 mM) for WT ex-
pressing cells (Fig. 4D–F), In contrast, cells expressing the other
five AP2r variants (Arg3His, Ala44Thr, Phe52Tyr, Arg61His and
Glu122Gly) had Ca2þi responses and EC50 values that were not sig-
nificantly different to the WT expressing cells, indicating that they
are likely to be benign polymorphisms and not mutations
(Supplementary Material, Fig. S3).
We have previously demonstrated that the elevated EC50
values for CaSR-mediated Ca2þi release in cells expressing the
FHH3-causing AP2r Arg15 mutations can be rectified by treatment
Figure 4. Intracellular calcium responses of cells expressing the AP2r variants (Thr112Met, Met117Ile and Glu142Lys) encoded by AP2S1 exon 5 and located in the AP2r a4-a5
helices. Ca2þi responses, measured by flow cytometry, to changes in [Ca
2þ]e of HEK-CaSR cells transfected with wild-type (WT), or (A) Thr112Met, (B) Met117Ile or (C) Glu142Lys
AP2r variants (v), or the FHH3-associated Arg15His mutant (m) constructs. The Ca2þi responses to changes in [Ca
2þ]e are expressed as a percentage of the maximum normalized
responses and shown as the mean6SEM of 4–8 independent transfections. The Thr112Met, Met117Ile and Glu142Lys AP2r variants led to a rightward shift in the concentration-
response curve (red line), compared to WT. Variant responses were similar to the Arg15His loss-of-function mutant (blue line). (D–F) Histograms showing the mean half-maxi-
mal concentration (EC50) with 95% confidence intervals (CI) and P-values of cells expressing WT (black bar), (D) Thr112Met, (E) Met117Ile or (F) Glu142Lys (red bars) and Arg15His
(blue bar) AP2r proteins. Statistical analysis was performed using the F-test. ****P< 0.0001, ***P< 0.001, compared to WT.
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with cinacalcet, which is a CaSR positive allosteric modulator (29).
To investigate whether the loss of function observed in HEK-CaSR
cells expressing the AP2r Thr112Met, Met117Ile or Glu142Lys mu-
tations may also be corrected by allosteric modulation, we tested
responses in the presence of 10 nM cinacalcet, a dose which nor-
malizes altered signalling responses of the FHH3-causing Arg15
AP2r mutations (29). Treatment with 10 nM cinacalcet, led to a
leftward shift of the abnormal dose–response curves for all three
variants (Fig. 5A–C), such that the EC50 values of AP2r variant
expressing cells were decreased and similar to values of WT AP2r
expressing cells [EC50 values without cinacalcet (n¼ 4–8) were 3.51
mM (95% CI 3.37–3.65 mM) for Thr112Met expressing cells
(P< 0.001), 3.41 mM (95% CI 3.29–3.54 mM) for Met117Ile expressing
cells (P< 0.0001) and 3.55 mM (95% CI 3.40–3.70 mM) for Glu142Lys
expressing cells (P< 0.0001); with cinacalcet treatment, EC50 values
(n¼ 4–8) were 3.01 mM (95% CI 2.87–3.16 mM) for Thr112Met ex-
pressing cells [P¼not significant (ns)], 2.84 mM (95% CI 2.70–3.00
mM) for Met117Ile expressing cells (P¼ns), and 3.04 mM (95% CI
2.94–3.14 mM) for Glu142Lys expressing cells (P¼ns), compared to
2.98 mM [(95% CI 2.87–3.10 mM) for WT expressing cells] (Fig. 5D–F).
Thus, cinacalcet is able to correct the loss of function associated
with the AP2r a4-a5 helix variants (Thr112Met, Met117Ile and
Glu142Lys).
Discussion
Our studies, which have analysed exome datasets from
112 000 individuals for AP2r variants that may cause FHH3
and abnormalities of CaSR-mediated signalling, provide several
new insights about: the prevalence of FHH3-associated AP2r
mutations, the structural-functional consequences of these mu-
tations; and the importance of the AP2r a4 and a5 helices in
mediating activation of the AP2 complex that has a critical role
in clathrin-mediated endocytosis of cell-surface proteins such
as GPCRs. Thus, our analysis of the DiscovEHR cohort, of adult
patients from a stable regional population in Pennsylvania (30),
has provided the first prevalence estimate for FHH3, and found
this to be 7.8 cases per 100 000, which is similar to the esti-
mated prevalence of 1–9 cases per 100 000 for FHH1 (31), and in
keeping with FHH being defined as a rare disease (32). Three out
of the five DiscovEHR patients with rare AP2r variants, had the
Arg15His AP2r mutation, which has been reported to cause a
milder form of hypercalcaemia than the FHH3-causing
Arg15Cys and Arg15Leu AP2r mutations (8). In keeping with
this, the Arg15His AP2r mutation in the DiscovEHR cohort was
associated with serum calcium concentrations that were mildly
elevated, in two patients, or at the upper limit of normal in one
patient (Table 1). The two patients with the Arg15His mutation,
who were hypercalcaemic, also had vitamin D deficiency and/or
chronic kidney disease, and this may have influenced their mild
hypercalcaemia (Table 1). In addition, our results reveal that
some individuals who are heterozygous for the AP2r Arg15His
may be normocalcaemic and this is similar to the reports that
heterozygous loss-of-function CaSR mutations, which are asso-
ciated with hypercalcaemia in the majority of patients may also
rarely be associated with normocalcaemia in some individuals
Figure 5. Effect of cinacalcet on intracellular calcium responses of cells expressing the AP2r variants Thr112Met, Met117Ile and Glu142Lys. Ca2þi responses, measured
by flow cytometry, to changes in [Ca2þ]e of HEK-CaSR cells transfected with wild-type (WT) or (A) Thr112Met, (B) Met117Ile or (C) Glu122Gly variants (v) AP2r proteins.
The Ca2þi responses to changes in [Ca
2þ]e are expressed as a percentage of the maximum normalized responses and shown as the mean6SEM of 4–8 independent
transfections. The Thr112Met, Met117Ile and Glu142Gly AP2r variants led to a rightward shift in the concentration–response curve (red line), compared to WT, and the
addition of 10 nM cinacalcet (cin) rectified these rightward shifts of the AP2r variants (blue line). (D–F) Histograms showing the mean half-maximal concentration
(EC50) with 95% confidence intervals (CI) and P-values of cells expressing WT (black bar), (D) Thr112Met, (E) Met117Ile and (F) Glu142Gly variants treated with vehicle
(red bars), or treated with 10 nM cinacalcet (blue bars) AP2r proteins. Statistical analysis was performed using the F-test. ****P < 0.0001, ***P < 0.001 compared to WT.
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(33,34). Moreover, our results are the first to report that an AP2r
mutation (Met117Ile) that does not involve the Arg15 residue
can impair CaSR-mediated signalling (Fig. 4), and may be associ-
ated with hypercalcaemia (Table 1), consistent with FHH3.
Thus, our findings indicate that non-Arg15 AP2r mutations
may cause FHH3, and that the current practice of only searching
for mutations of the AP2r Arg15 residues in exon 2 will need to
be altered to include DNA sequence analysis of the other AP2S1
exons.
Indeed, our demonstration that mutations (e.g. Thr112Met,
Met117Ile and Glu142Lys) located in the AP2r a4-a5 helices im-
pair the intracellular calcium signalling responses of CaSR-
expressing cells (Fig. 4, Supplementary Material, Table S4) indi-
cate the importance of this region for CaSR signalling and/or
clathrin-mediated endocytosis. Our structural studies predicted
that variations in the AP2r a4-a5 helices would disrupt contacts
with the AP2a subunit, and thus are likely to impair AP2 com-
plex formation and/or the conformational changes necessary
for AP2 complex activation (Fig. 3, Supplementary Material,
Table S4). Indeed, in previous studies in which AP2a was deleted
in C. elegans, the AP2r homolog was shown to be unstable,
whilst the contacts between AP2b and AP2m (which represents
the other heterodimer in the AP2 structure) were unaffected
(13). Thus, these previous studies and our investigation of AP2r
a4-a5 variants suggest that mutations located at the AP2r–AP2a
interface are likely to impair heterodimer function. These stud-
ies also indicate that AP2r mutations could be divided into two
types: those impairing cargo protein recognition, as is the case
for Arg15 mutations; and those impairing AP2 complex acti-
vation, as is the case for AP2r a4-a5 mutants. In addition, our in
vitro investigations demonstrated that the CaSR-positive al-
losteric modulator, cinacalcet, can normalize the impaired
signalling responses associated with mutations (Thr112Met,
Met117Ile and Glu142Lys) of the AP2r a4-a5 helices, and this is
similar to our previous report that cinacalcet can rectify the in
vitro and in vivo abnormalities of CaSR-mediated signalling
associated with AP2r Arg15 mutants (29). Thus, cinacalcet
may have therapeutic potential for patients who have such
AP2r mutations located in the a4-a5 helices, together
with symptomatic hypercalcaemia or additional clinical
phenotypes such as cognitive dysfunction that have been ob-
served in patients with FHH3-causing Arg15 AP2r mutations
(8,29).
Our findings also highlight the importance of functional
characterization of variants identified in large-scale sequencing
databases (e.g. ExAc), to assess whether these may represent
pathogenic mutations. Thus, population cohorts that contain
sequencing data on patients with a range of disorders [including
diabetes mellitus type 2, heart disease and inflammatory bowel
disease (24)], should be used with caution as representative of
the ‘normal’ population. Furthermore, in the absence of clinical
data, from the ExAc and dbSNP databases, it is difficult to deter-
mine whether the carriers within the cohort are unaffected by
the disorder under investigation. However, the DiscovEHR
cohort, which has available both genetic and clinical data (26),
allows assessment of the pathogenic effect of genetic variants.
In addition, our studies illustrate the reliability and difficulties
associated with the pathogenicity prediction and three-
dimensional modelling programs (Supplementary Material,
Table S4). Thus, the pathogenicity and three-dimensional
modelling programs predicted that the AP2r variants
Thr112Met and Glu142Lys would likely be deleterious (Fig. 3 and
Supplementary Material, Table S2) and that Ala44Thr would
likely not be deleterious (Fig. 2 and Supplementary Material,
Table S2), and this was found to be in agreement with the in vi-
tro studies that assessed the effects of these variants on CaSR-
mediated Ca2þi signalling (Fig. 4 and Supplementary Material,
Fig. S3). However, for other AP2r variants such pathogenicity
and three-dimensional modelling programs were not of value
when used alone in correctly predicting the effect of the genetic
variants. For example, two of the AP2r variants, Arg61His and
Glu122Gly, were predicted to be deleterious (Figs 2 and 3,
Supplementary Material, Table S2), but were instead found to
have no effect on CaSR-mediated Ca2þi signalling (Supplementary
Material, Fig. S3); while another, Met117Ile, which was predicted to
be likely deleterious by pathogenicity programs (Supplementary
Material, Table S1) but not three-dimensional modelling (Fig. 3)
had impaired signalling (Fig. 4) and was associated with hypercal-
caemia in the patient (Table 1). Finally, for the Arg3His and
Phe52Tyr AP2r variants, the pathogenicity and three-dimensional
modelling programs gave different predictions (Fig. 2 and
Supplementary Material, Tables S1 and S2), and both of these were
shown by in vitro studies to not result in impaired CaSR signalling
(Supplementary Material, Fig. S3), and the Phe52Tyr variant to be
associated with normocalcaemia in the patient (Table 1). Thus, it is
important to investigate such genetic variants from large-scale se-
quencing databases with a range of different methods that include
population data combined with clinical information, prediction
programs, structural models and in vitro functional studies, to es-
tablish variant pathogenicity.
In conclusion, our studies have identified that non-Arg15
AP2r mutations may be associated with impaired CaSR-
mediated Ca2þi signalling and hypercalcaemia, and that such
mutations may cluster at the AP2r–AP2a inter-subunit inter-
face, and disrupt formation of the AP2 complex with deleterious
effects on CaSR function and Ca2þe homeostasis.
Materials and Methods
Ethics statement
All clinical data and unique International Classification of
Disease-9 (ICD9) codes for each patient were obtained from the
electronic health records (EHR) in a de-identified manner through
an approved data broker, in accordance with Institutional Review
Board approvals (26,30).
DiscovEHR patient cohort
The study cohort has previously been described in detail (26).
In brief, the cohort consisted of Geisinger Health System (GHS)
patients within the MyCode Community Health Initiative (26),
and whose germ-line DNA underwent whole exome sequenc-
ing. Participants were 59% females and 41% males, with a me-
dian age of 61 years, and predominantly White (98%) and were
enrolled through primary care and specialty outpatient clinics.
Exome sequencing was performed as described previously
(26). Details of sample preparation, sequencing, sequence
alignment, variant identification, genotype assignment and
quality control steps, including the setting of allele balance
at<0.7, high quality combined allele read depth (AD) of8
reads and per sample genotype quality (GQ) of30, have been
described previously (26).
Online exome and genome sequencing datasets
Two online datasets [ExAc (http://exac.broadinstitute.org/) (24),
which includes the 1000 Genomes dataset (http://www.interna
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tionalgenome.org), and dbSNP (https://www.ncbi.nlm.nih.gov/
projects/SNP/; date last accessed November 2017)] that contain
population-based sequencing information from>60 706 unre-
lated individuals were used.
Protein sequence alignment and three-dimensional
modeling of AP2r structure
Protein sequences of AP2r orthologs aligned using
ClustalOmega (http://www.ebi.ac.uk/Tools/msa/clustalo/; date
last accessed November 2017) (35). SIFT (http://sift.jcvi.org/; date
last accessed November 2017) and Polyphen-2 (http://genetics.
bwh.harvard.edu/pph2/; date last accessed November 2017)
were used to predict the effect of amino acid substitutions
(36,37). AP2r secondary structure was studied using Spider2
(38). AP2r three-dimensional modelling was undertaken using
the reported AP2 structures (Protein Data Bank accession num-
bers 2XA7 and 2JKR) (10,12). Molecular modelling was performed
using the PyMOL Molecular Graphics System (Version1.2r3pre,
Schro¨dinger, LL Pymol) (25).
Cell culture, constructs and antibodies
Functional assessments of the AP2r variants were performed us-
ing HEK293 cells stably expressing the full-length CaSR (HEK-
CaSR), as described previously (3,18). Cells were maintained in
DMEM-Glutamax media (ThermoFisher) with 10% fetal bovine se-
rum (Gibco) and 400mg/mL geneticin (ThermoFisher) at 37C, 5%
CO2. Wild-type and mutant pBI-CMV4-AP2S1 expression con-
structs were generated (using GenBank Accession Number:
NM_021575.3), as described (8), and transiently transfected into
HEK-CaSR cells using Lipofectamine 2000 (LifeTechnologies). The
bidirectional pBI-CMV4 cloning vector was used as it facilitated
the co-expression of AP2r and RFP (8), and site-directed mutagen-
esis was used to generate the mutant AP2S1 constructs using the
Quikchange Lightning Site-directed Mutagenesis kit (Agilent
Technologies) and gene-specific primers (SigmaAldrich), as de-
scribed (39). The presence of mutations was verified using dideox-
ynucleotide sequencing with the BigDye Terminator v3.1 Cycle
Sequencing Kit (Life Technologies) and an automated detection
system (ABI3730 Automated capillary sequencer; Applied
Biosystems) (39). Successful transfection was confirmed by visual-
izing RFP fluorescence using an Eclipse E400 fluorescence micro-
scope with a Y-FL Epifluorescence attachment and a triband 4,6-
diamidino-2-phenylindole-FITC-Rhodamine filter, and images
captured using a DXM1200C digital camera and NIS Elements soft-
ware (Nikon) (3,8,18). The expression of AP2r was also determined
by western blot analysis using an anti-AP2r antibody (Abcam)
and expression of calnexin, used as a control, was determined by
western blot analysis using an anti-calnexin antibody (Millipore).
The western blots were visualized using an Immuno-Star
WesternC kit (BioRad) on a BioRad Chemidoc XRSþ system (3).
Intracellular calciummeasurements
The Ca2þi responses of HEK-CaSR cells expressing WT or mutant
AP2r proteins were assessed by a flow cytometry-based assay,
as reported (3,8,18). In brief, HEK-CaSR cells were cultured in
T75 flasks and transiently transfected 24 h later with 8mg DNA
(3). Forty-eight hours following transfection, the cells were de-
tached, resuspended in Ca2+ -and Mg2+-free Hanks’ buffered sa-
line solution (HBSS) and loaded with 1mg/mL Indo-1-
acetoxymethylester (Indo-1-AM) for 1 h at 37C. Transfected
HEK-CaSR cells were incubated with either a 20% aqueous solu-
tion of 2-hydroxypropyl-b-cyclodextrin (Sigma) (vehicle) or 10
nM cinacalcet-HCl (Cambridge Bioscience Ltd.), resuspended in
vehicle and added to cells prior to flow cytometry analysis (29).
After the removal of free dye, cells were resuspended in Ca2þ-
and Mg2þ-free HBSS and maintained at 37C. Transfected cells,
in suspension, were stimulated by sequentially adding Ca2þ to
the Ca2þ- and Mg2þ-free HBSS to increase the [Ca2þ]e in a step-
wise manner from 0 to 15 mM, and then analysed on a MoFlo
modular flow cytometer (Beckman Coulter) by simultaneous
measurements of RFP expression (at 525 nm), Ca2þi-bound Indo-
1-AM (at 410 nm) and free Indo-1-AM (i.e. not bound to Ca2þi) (at
485 nm), using a JDSU Xcyte UV laser (Coherent Radiation), on
each cell at each [Ca2þ]e, as described (3,18). The peak mean
fluorescence ratio of the Ca2þi transient response after each in-
dividual stimulus was measured using Cytomation Summit
software (Beckman Coulter), and expressed as a normalized re-
sponse, as described (3,18). Nonlinear regression of concentra-
tion–response curves was performed with GraphPad Prism
using the normalized response at each [Ca2þ]e for each separate
experiment for the determination of EC50 (i.e. [Ca
2þ]e required
for 50% of the maximal response). The mean EC50 obtained from
four to eight separate transfection experiments were used for
statistical comparison by using the F-test (3,8,18).
Supplementary Material
Supplementary Material is available at HMG online.
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